LAVA Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LAVA-051 / LAVA Therap
2020-004583-26: A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia

Not yet recruiting
1/2
222
Europe
LAVA-051, LAVA-051, Concentrate for solution for injection/infusion
LAVA Therapeutics N.V., LAVA Therapeutics NV, LAVA Therapeutics B.V., LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML), Patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04887259 / 2020-004583-26: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Checkmark Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark First patient dosing for P1/2a for relapsed refractory CLL
More
Terminated
1
16
Europe, US
LAVA-051, Interleukin 2
Lava Therapeutics, LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
09/23
09/23
LAVA-1207 / LAVA Therap
2021-001789-39: LAVA-1207 Open Label study in patients with therapy refractory metastatic castration resistant prostate cancer

Ongoing
1/2
66
Europe
LAVA-1207, NA, Infusion
LAVA Therapeutics N.V., LAVA Therapeutics N.V.
Prostate Cancer, Prostate Cancer, Diseases [C] - Cancer [C04]
 
 
KEYNOTE F73, NCT05369000: Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Active, not recruiting
1/2
180
Europe, US
LAVA-1207, LAVA-1207 plus Pembrolizumab
Lava Therapeutics, Merck Sharp & Dohme LLC
Metastatic Castration Resistant Prostate Cancer
04/27
04/27
PF-08046052 / Pfizer
SGNEGFRd2-001, NCT05983133: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Recruiting
1
290
Europe, US
PF-08046052, SGN-EGFRd2
Seagen, a wholly owned subsidiary of Pfizer
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
01/29
01/30
LAVA-1266 / LAVA Therap
ACTRN12624001214527: A clinical trial to assess the safety, distribution, effects on certain immune cells and anti-leukaemia effects of LAVA-1266 in patients with acute myeloid leukaemia or certain types of myelodysplastic syndrome

Recruiting
1
50
 
LAVA Therapeutics N.V., LAVA Therapeutics (Australia) Pty Ltd
Acute myeloid leukaemia (AML) , Refractory/Relapsed (R/R) acute myeloid leukaemia (AML) , Intermediate risk myelodysplastic syndrome (MDS), High risk myelodysplastic syndrome (MDS), Extremely high risk myelodysplastic syndrome (MDS)
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LAVA-051 / LAVA Therap
2020-004583-26: A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia

Not yet recruiting
1/2
222
Europe
LAVA-051, LAVA-051, Concentrate for solution for injection/infusion
LAVA Therapeutics N.V., LAVA Therapeutics NV, LAVA Therapeutics B.V., LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML), Patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04887259 / 2020-004583-26: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Checkmark Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark First patient dosing for P1/2a for relapsed refractory CLL
More
Terminated
1
16
Europe, US
LAVA-051, Interleukin 2
Lava Therapeutics, LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
09/23
09/23
LAVA-1207 / LAVA Therap
2021-001789-39: LAVA-1207 Open Label study in patients with therapy refractory metastatic castration resistant prostate cancer

Ongoing
1/2
66
Europe
LAVA-1207, NA, Infusion
LAVA Therapeutics N.V., LAVA Therapeutics N.V.
Prostate Cancer, Prostate Cancer, Diseases [C] - Cancer [C04]
 
 
KEYNOTE F73, NCT05369000: Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Active, not recruiting
1/2
180
Europe, US
LAVA-1207, LAVA-1207 plus Pembrolizumab
Lava Therapeutics, Merck Sharp & Dohme LLC
Metastatic Castration Resistant Prostate Cancer
04/27
04/27
PF-08046052 / Pfizer
SGNEGFRd2-001, NCT05983133: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Recruiting
1
290
Europe, US
PF-08046052, SGN-EGFRd2
Seagen, a wholly owned subsidiary of Pfizer
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
01/29
01/30
LAVA-1266 / LAVA Therap
ACTRN12624001214527: A clinical trial to assess the safety, distribution, effects on certain immune cells and anti-leukaemia effects of LAVA-1266 in patients with acute myeloid leukaemia or certain types of myelodysplastic syndrome

Recruiting
1
50
 
LAVA Therapeutics N.V., LAVA Therapeutics (Australia) Pty Ltd
Acute myeloid leukaemia (AML) , Refractory/Relapsed (R/R) acute myeloid leukaemia (AML) , Intermediate risk myelodysplastic syndrome (MDS), High risk myelodysplastic syndrome (MDS), Extremely high risk myelodysplastic syndrome (MDS)
 
 

Download Options